Genmab A/S (GMAB) Stock Forecast & Price Target

$19.31 +0.50 (+2.66%)

As of 03:39 PM Eastern

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
3

Buy
9

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 3 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$39.17
102.83% Upside

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $39.17. The highest price target for GMAB is $48.00, while the lowest price target for GMAB is $27.00. The average price target represents a forecasted upside of 102.83% from the current price of $19.31.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

GMAB Analyst Ratings Over Time

Type	Current Forecast 4/14/24 to 4/14/25	1 Month Ago 3/15/24 to 3/15/25	3 Months Ago 1/15/24 to 1/14/25	1 Year Ago 4/15/23 to 4/14/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$39.17	$41.33	$45.20	$48.50
Forecasted Upside	102.83% Upside	101.53% Upside	108.87% Upside	65.76% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Remove Ads

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	102.73% Upside	23,135.64% Upside	25.78% Upside
News Sentiment Rating	Positive News See Recent GMAB News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/9/2025	HC Wainwright 1 of 5 stars	Raghuram Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00	+105.78%
4/1/2025	Sanford C. Bernstein 3 of 5 stars	J. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/11/2025	Truist Financial 2 of 5 stars	Asthika Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$50.00 ➝ $45.00	+122.28%
3/11/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/13/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jonathan Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$27.00	+37.13%
2/11/2025	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Floc'h Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
11/8/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$46.00 ➝ $48.00	+110.25%
10/8/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$31.00 ➝ $31.00	+15.63%
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
8/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:59 PM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, April 6, 2025. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

Genmab A/S recently reported earnings per share (EPS) of $0.57, significantly exceeding the consensus estimate of $0.28, indicating strong financial performance and potential for growth.
The current stock price is $20.24, which may present a buying opportunity for investors looking for undervalued stocks in the biotechnology sector.
Institutional investors have shown increased interest, with PNC Financial Services reducing its stake by only 20.1%, while others like Charles Schwab raised their stake by 94.1%, suggesting confidence in the company's future.
Genmab A/S has a solid market capitalization of approximately $13.40 billion, which reflects its stability and potential for further growth in the competitive biotech market.
Analysts have a consensus rating of "Moderate Buy" with an average target price of $41.33, indicating that there is significant upside potential for the stock based on current valuations.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

Despite recent positive earnings, the stock has a price-to-earnings (P/E) ratio of 11.63, which may suggest that the stock is not as undervalued as it appears, especially in a high-growth sector like biotechnology.
The stock has experienced volatility, with a 1-year low of $18.64 and a high of $31.02, indicating potential risks associated with price fluctuations that could affect investor returns.
Only 7.07% of the stock is currently owned by institutional investors, which may indicate a lack of confidence from larger investment firms in the company's long-term prospects.
Recent price target adjustments by analysts, such as Truist Financial lowering their target from $50.00 to $45.00, may reflect concerns about the company's growth trajectory and market conditions.
With a beta of 0.98, the stock's price movements are closely aligned with the market, suggesting that it may not provide the diversification benefits that some investors seek in a volatile market environment.

GMAB Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $39.17, with a high forecast of $48.00 and a low forecast of $27.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMAB shares.
: According to analysts, Genmab A/S's stock has a predicted upside of 102.83% based on their 12-month stock forecasts.
: Over the previous 90 days, Genmab A/S's stock had 4 upgrades and 1 downgrade by analysts.
: Genmab A/S has been rated by research analysts at BNP Paribas, HC Wainwright, Leerink Partners, Leerink Partnrs, Sanford C. Bernstein, Truist Financial, and William Blair in the past 90 days.
: Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.69 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:GMAB) was last updated on 4/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Stock Forecast & Price Target